|
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Capitalization1 |
94 860 | 132 331 | 131 461 | 146 061 | - | - |
| Entreprise Value (EV)2 |
109 142 | 144 340 | 143 328 | 156 945 | 156 482 | 155 510 |
| P/E ratio |
44,0x | 97,9x | 41,0x | 32,2x | 25,1x | 18,5x |
| Yield |
3,74% | 2,78% | 2,80% | 2,57% | 2,66% | 2,79% |
| Capitalization / Revenue |
4,29x | 5,43x | 4,94x | 4,70x | 4,18x | 3,85x |
| EV / Revenue |
4,94x | 5,92x | 5,38x | 5,05x | 4,48x | 4,10x |
| EV / EBITDA |
15,3x | 21,6x | 17,2x | 16,0x | 13,1x | 10,7x |
| Price to Book |
7,61x | 10,00x | 8,41x | 8,95x | 7,62x | 6,16x |
| Nbr of stocks (in thousands) |
1 266 812 | 1 311 913 | 1 312 660 | 1 312 762 | - | - |
| Reference price (USD) |
74,9 | 101 | 100 | 111 | 111 | 111 |
| Last update |
02/14/2019 | 02/14/2020 | 02/11/2021 | 05/12/2021 | 05/12/2021 | 05/12/2021 |
|
1 GBP in Million 2 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Net sales1 |
22 090 | 24 384 | 26 617 | 31 079 | 34 917 | 37 966 |
| EBITDA1 |
7 140 | 6 686 | 8 311 | 9 787 | 11 976 | 14 542 |
| Operating profit (EBIT)1 |
5 672 | 6 436 | 7 340 | 8 919 | 10 632 | 12 721 |
| Operating Margin |
25,7% | 26,4% | 27,6% | 28,7% | 30,4% | 33,5% |
| Pre-Tax Profit (EBT)1 |
1 993 | 1 548 | 3 916 | 4 734 | 7 318 | 9 597 |
| Net income1 |
2 155 | 1 335 | 3 196 | 4 531 | 5 821 | 7 741 |
| Net margin |
9,76% | 5,47% | 12,0% | 14,6% | 16,7% | 20,4% |
| EPS2 |
1,70 | 1,03 | 2,44 | 3,45 | 4,41 | 5,98 |
| Dividend per Share2 |
2,80 | 2,80 | 2,80 | 2,85 | 2,95 | 3,09 |
| Last update |
02/14/2019 | 02/14/2020 | 02/11/2021 | 05/13/2021 | 05/13/2021 | 05/13/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Net Debt1 |
14 282 | 12 009 | 11 867 | 10 883 | 10 420 | 9 449 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
2,00x | 1,80x | 1,43x | 1,11x | 0,87x | 0,65x |
| Free Cash Flow1 |
1 575 | 1 990 | 3 838 | 7 307 | 7 354 | 7 655 |
| ROE (Net Profit / Equities) |
32,0% | 35,6% | 36,7% | 39,3% | 44,0% | 44,1% |
| Shareholders' equity1 |
6 742 | 3 752 | 8 704 | 11 521 | 13 240 | 17 550 |
| ROA (Net Profit / Asset) |
7,07% | 2,19% | 4,99% | 5,20% | 6,30% | 7,00% |
| Assets1 |
30 480 | 61 015 | 64 053 | 87 130 | 92 402 | 110 587 |
| Book Value Per Share2 |
9,84 | 10,1 | 11,9 | 12,4 | 14,5 | 18,0 |
| Cash Flow per Share2 |
2,07 | 2,28 | 3,66 | 2,85 | 6,12 | 7,88 |
| Capex1 |
1 043 | 979 | 961 | 1 368 | 1 463 | 1 621 |
| Capex / Sales |
4,72% | 4,01% | 3,61% | 4,40% | 4,19% | 4,27% |
| Last update |
02/14/2019 | 02/14/2020 | 02/11/2021 | 05/13/2021 | 05/13/2021 | 05/13/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
AstraZeneca runs into 'meaningful' investor revolt over pay |
Capitalization (GBP) 103 642 560 373 Capitalization (USD) 146 331 992 564 Net sales (USD) 26 617 000 000 Number of employees 76 100 Sales / Employee (USD) 349 763 Free-Float capitalization (GBP) 99 232 769 516 Free-Float capitalization (USD) 140 105 848 782 Avg. Exchange 20 sessions (USD) 15 201 906 977 Average Daily Capital Traded 14,7%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
